Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TORCH: ATG-008 in HBV+ Advanced HCC
NCT03591965Phase 2Terminated
- Sponsor
- Antengene
- Start
- Aug 2018
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of onatasertib in hepatocellular carcinoma (HCC), sponsored by Antengene. Started Aug 2018; status: terminated.
02
Drugs
onatasertib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03591965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03591965.